ASX:TLXBiotechs
How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Expanding Radiopharma Platform And Streamlining Incentives
Recent news shows Telix Pharmaceuticals continuing to build out its radiopharmaceutical franchise, with Illuccix now commercially available in 17 countries and preparations under way to launch Gozellix, supported by expanded manufacturing and distribution capacity via the RLS Pharma acquisition.
An underappreciated development is the lapse of several conditional share and appreciation rights, which reduces potential future dilution and simplifies Telix’s capital structure, refining how...